Revolutionizing Medicine Through Pharmacogenomics®, Gentris Corporation is a global provider of applied clinical pharmacogenomic services and diagnostic products. As pioneers in the field of pharmacogenomics, Gentris helps pharmaceutical companies and CROs effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market sooner.

Innovative Solutions
Gentris Corporation is a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions. As pioneers in the field of pharmacogenomics, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market more quickly.

Gentris is developing diagnostic test kits and validated reference controls that will bring the promise of personalized medicine to physicians and patients, which will enhance patient management, improve patients' response to therapy and revolutionize medicine through pharmacogenomics.

Pharmacogenomics
The use of an individual's genetic profile to more accurately predict the safety, toxicity and efficacy of drugs - and ultimately to improve an individual's treatment and prognosis.

Overview
Gentris Corporation is transforming global drug development with clinical pharmacogenomic solutions that can accelerate drug development and significantly reduce costs, resulting in more predictable response to drug therapy and less frequent, less severe adverse drug reactions (ADRs).

For every 5,000 drug candidates that enter pre-clinical testing, the Food and Drug Administration will approve only one. As a result, pharmaceutical organizations are under pressure to reduce costs and to address the key reasons for drug failure - ADRs, lack of efficacy and unfavorable pharmacokinetics/drug metabolism properties.

ADRs are currently the fourth leading cause of death and the fifth leading cause of illness in the United States. Gentris helps reduce this statistic with clinical pharmacogenomic testing that will identify patients that may exhibit drug intolerance earlier in the development cycle. With better characterization of patient populations, pharmacogenomics can help reduce drug failure rates by enabling drug companies to modify patients' exposure to drugs based on their drug-response genotype. This can offer the added benefit of making drugs that might otherwise not be approved or withdrawn to become available to patients with compatible pharmacogenomic profiles. Other benefits include shorter and more focused clinical trials that offer the promise of getting drugs to market faster, with higher safety profiles and at lower cost.

Company Mission
Gentris Corporation will lead the new paradigm in healthcare by enabling the administration of medication based on individual genetic variation by offering high quality pharmacogenomic laboratory testing services and diagnostic products.

Management Team

Michael Murphy, President and CEO
L. Scott Clark, Ph. D., Vice President, Research and Development
Heath Knight, Ph. D., Vice President, Business Development
Dawn Bordeaux, RQAP-GLP, Vice President, Quality Assurance and Regulatory Affairs
Pamela Nakhle, Ph. D., Executive Director, Product Development
Dean Watson, Executive Director, Product Operations
Karen Nield, Vice President, Finance and Human Resources

Key Contact Information

Diane M. Washburn
Marketing
Direct: 919-653-5520
washburnd@gentris.com

Last Updated: 02-06-2007